Search | Page 19 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes

    ... Low endogenous erythropoietin levels and limited red blood cell transfusion history can predict response to ...

    Research Article last updated 08/04/2014 - 8:33am.

  2. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... During the study, six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by ...

    Research Article last updated 01/20/2015 - 2:28pm.

  3. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab.

    ... BACKGROUND: Pure red cell aplasia and moderate aplastic anemia are marrow failure ... Previously, we described short-term improvements in blood counts in two pilot studies treating moderate aplastic anemia (mAA) and ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Clinical Trials Report for December 2015

    ... marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative ...

    Page last updated 11/30/2015 - 10:31am.

  5. Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia

    ... on our trial went on successfully to have allogeneic stem cell transplantation. Are there any side effects? Very few. At ... National Institutes of Health, National Heart, Lung, and Blood Institute ...

    Interview last updated 07/06/2012 - 3:42pm.

  6. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... Journal Title:  Blood Primary Author:  ... cytogenetics , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) ...

    Research Article last updated 07/28/2014 - 8:53am.

  7. What is MDS? iPad App

    ... materials provide information about why MDS results in low blood counts, such as anemia (low red blood cell count), neutropenia (low white blood cell ...

    Page last updated 10/28/2015 - 2:31pm.

  8. The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes

    ... patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose ...

    Research Article last updated 06/02/2014 - 11:03am.

  9. Polymorphism of the complement receptor 1 gene correlates with hematological response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

    ... the response is variable and some patients remain red blood cell transfusion -dependent. In 72 patients with hemolytic Paroxysmal ...

    Research Article last updated 09/26/2013 - 3:28pm.

  10. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... mg at 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were ...

    Research Article last updated 07/29/2014 - 12:12pm.